Compare FSP & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSP | SCYX |
|---|---|---|
| Founded | 1981 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.2M | 51.4M |
| IPO Year | 2001 | 2014 |
| Metric | FSP | SCYX |
|---|---|---|
| Price | $0.33 | $4.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | ★ 645.1K | 59.6K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 6.34% | N/A |
| EPS Growth | 15.69 | ★ 61.36 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $107,162,000.00 | $257,000.00 |
| Revenue This Year | $17.91 | N/A |
| Revenue Next Year | N/A | $608.78 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.34 | $0.57 |
| 52 Week High | $1.71 | $6.09 |
| Indicator | FSP | SCYX |
|---|---|---|
| Relative Strength Index (RSI) | 26.10 | 36.28 |
| Support Level | N/A | $0.67 |
| Resistance Level | $0.41 | $5.56 |
| Average True Range (ATR) | 0.02 | 0.29 |
| MACD | -0.01 | -0.14 |
| Stochastic Oscillator | 0.50 | 0.00 |
Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The principal revenue sources for its real estate operations include rental income from real estate leasing, property dispositions and fee income from asset/property management and development. The company provides asset management, property management, property accounting, investor and/or development services to its portfolio and Sponsored REIT through the company's subsidiaries.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.